Author

M. Fiorentino

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:batch correction / integration· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Approach:experimental assay· 1

Frequent Co-Authors

M. Loda· 2 shared A. Alaimo· 1 shared A. Antoccia· 1 shared A. Bertossi· 1 shared A. Bisio· 1 shared A. Lunardi· 1 shared A. Romanel· 1 shared B. Gyorffy· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPathology

M. Loda

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays

K. H. Stopsack, S. Tyekucheva, M. Wang, T. A. Gerke, J. B. Vaselkiv, K. L. Penney, P. W. Kantoff, S. P. Finn, M. Fiorentino, M. Loda, T. L. Lotan, G. Parmigiani, L. A. Mucci

This study assesses batch effects in TMA-based cancer biomarker studies and shows mitigation methods reduce variance and alter clinical associations.

bioRxiv · Jun 29, 2021Pathology

Intra-epithelial non-canonical Activin A signalling safeguards prostate progenitor quiescence

F. Cambuli, V. Foletto, A. Alaimo, D. De Felice, F. Gandolfi, M. D. Palumbieri, M. Zaffagni, S. Genovesi, M. Lorenzoni, M. Celotti, E. Bertossio, G. Mazzero, A. Bertossi, A. Bisio, F. Berardinelli, , A. Lunardi

This study identifies non-canonical Activin A signaling as a mechanism maintaining prostate epithelial progenitor quiescence, with implications for cancer and therapy.

bioRxiv · Mar 5, 2021 · PreprintCancer Biology

Pharmacological inhibition of the ALK axis elicits therapeutic potential in Consensus Molecular Subtype 1 colon cancer patients

M. Mazzeschi, M. Sgarzi, D. Romaniello, V. Gelfo, C. Cavallo, S. Santi, M. Fiorentino, G. D'Uva, B. Gyorffy, R. Palmer, M. Lauriola

This study shows that ALK inhibition improves outcomes in CMS1 colon cancer patients by reducing cell proliferation and enhancing cell adhesion.

bioRxiv · Oct 7, 2020 · PreprintCancer Biology